GO:0015732 prostaglandin transport: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015732 prostaglandin transport describes the directed movement of prostaglandins into, out of, or within cells by transporters or pores.
• The prostaglandin transporter SLCO2A1 is the central plasma membrane carrier for prostaglandin uptake and clearance, and its structure and transport cycle have been resolved.
• Prostaglandin transport controls local prostaglandin concentrations and therefore modulates inflammation, pain, fever, vascular tone, and reproduction.
• Transport across blood-brain barriers and erythrocyte membranes is carrier-mediated and pharmacologically relevant for prostaglandin analogues.
• SLCO2A1 transport activity is regulated by protein partners such as annexin A2 and S100A10, linking transport to membrane trafficking and signaling.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of prostaglandin transport genes in disease and drug-response studies.
Description
Prostaglandin transport (GO:0015732) is the biological process by which prostaglandins are moved into, out of, or between cells by dedicated transporters or pores. Prostaglandins are lipid mediators synthesized locally and acting near their sites of production, so their biological effects depend critically on how they are released, taken up, and cleared. The process therefore determines the intensity and duration of prostaglandin signaling in inflammation, pain, fever, vascular biology, and reproduction. Researchers study prostaglandin transport to understand how lipid mediators are distributed in tissues and how transport inhibitors or genetic variants alter prostaglandin action. The best-characterized transporter is SLCO2A1, a member of the organic anion transporting polypeptide family, which mediates prostaglandin uptake and clearance across cell membranes. Recent structural studies have defined the architecture and transport mechanism of human SLCO2A1, providing a framework for interpreting disease mutations and designing transport-modulating experiments. Transport at specialized barriers, including the blood-brain barrier and erythrocyte membrane, further shapes prostaglandin availability in the central nervous system and circulation. Because prostaglandin transport is a discrete, genetically tractable process, it is well suited to CRISPR-based functional genomics and cell-model studies.
prostaglandin transport At A Glance
| GO ID | GO:0015732 |
|---|---|
| GO term | prostaglandin transport |
| Ontology | biological_process |
| Synonym | none listed in QuickGO |
| Definition | The directed movement of prostaglandins into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| Major function | Carrier-mediated uptake, efflux, and distribution of prostaglandins such as PGE2, PGD2, and PGE1 |
| Key transporter | SLCO2A1 (prostaglandin transporter, PGT) |
| Representative tissues | Blood-brain barriers, erythrocytes, kidney, lung, and reproductive tissues |
| Disease relevance | Altered prostaglandin transport is linked to inflammation, barrier function, and drug disposition |
What Is GO:0015732?
According to the Gene Ontology, GO:0015732 prostaglandin transport is defined as the directed movement of prostaglandins into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. In practical terms, this covers carrier-mediated uptake, efflux, and transcellular movement of prostaglandin molecules, including prostaglandin E2, D2, E1, and related prostanoids, rather than their synthesis or receptor signaling. The process is distinct from prostaglandin biosynthesis and from prostaglandin receptor signal transduction, although it regulates both by controlling ligand availability.
Why Is prostaglandin transport Important in Cell Biology?
Prostaglandin transport is important because prostaglandins act as short-range lipid mediators whose local concentration is set by transport as much as by synthesis. By moving prostaglandins across membranes, transporters such as SLCO2A1 terminate or amplify signaling, control clearance from the circulation, and determine access to receptors in target tissues. This process influences inflammation, pain, fever, vascular tone, and reproductive physiology, and it affects the pharmacokinetics of prostaglandin analogues used clinically. Consequently, genetic or pharmacological manipulation of prostaglandin transport can change disease phenotypes and drug responses, making it a meaningful target for functional genomics and therapeutic research.
• Sets local prostaglandin concentrations and thereby controls the strength and duration of prostaglandin signaling.
• Mediates prostaglandin uptake and clearance by SLCO2A1, a key determinant of systemic prostaglandin levels.
• Regulates prostaglandin access to the central nervous system across blood-brain barriers.
• Contributes to prostaglandin handling by erythrocytes, affecting circulating prostaglandin pools.
• Modulates inflammation, pain, and fever by controlling prostaglandin availability at sites of injury.
• Influences vascular and reproductive biology through prostaglandin distribution in tissues.
• Affects pharmacokinetics and pharmacodynamics of prostaglandin analogue drugs.
• Provides a genetically tractable process for CRISPR screens and cell-model studies.
• Links membrane transport machinery to lipid mediator biology and drug transport.
• Offers candidate mechanisms for diseases involving prostaglandin dysregulation and barrier dysfunction.
What Happens During prostaglandin transport?
Substrate recognition at the plasma membrane
In simple terms: The transporter first recognizes and binds a prostaglandin molecule at the cell surface.
Prostaglandin transport begins when a carrier protein in the plasma membrane binds a prostaglandin substrate such as PGE2 or PGD2. SLCO2A1 is the principal prostaglandin transporter and recognizes prostaglandins with high specificity relative to many other organic anions. Structural studies of human SLCO2A1 have revealed a substrate-binding pocket that accommodates prostaglandins and related drugs, explaining the basis of substrate recognition. This step determines which prostaglandins and analogues can be transported and is therefore central to the selectivity of the process.
Translocation across the membrane
In simple terms: After binding, the transporter changes shape to move the prostaglandin across the membrane.
Following substrate binding, SLCO2A1 undergoes conformational changes that translocate the prostaglandin across the lipid bilayer. The transport cycle is thought to alternate between outward-facing and inward-facing states, allowing directed movement of prostaglandin into or out of the cell. This mechanism is consistent with carrier-mediated transport rather than simple diffusion, as established in early molecular studies of prostaglandin transport. The direction of net movement depends on the cellular context and on the concentration gradient of prostaglandin across the membrane.
Uptake and intracellular delivery
In simple terms: Once inside the cell, the prostaglandin can be delivered to intracellular sites or metabolized.
In uptake mode, prostaglandin transporters move extracellular prostaglandins into the cytoplasm, where they can interact with intracellular targets or be degraded. SLCO2A1-mediated uptake is a major route for clearing prostaglandins from the extracellular space and for delivering them to metabolizing enzymes. This uptake function is important in tissues such as kidney and lung, where prostaglandin clearance regulates local mediator levels. The process also contributes to the cellular distribution of prostaglandin analogues used pharmacologically.
Efflux and transcellular movement
In simple terms: Prostaglandins can also be moved out of cells or across cell layers to reach their targets.
Prostaglandin transport includes efflux from cells and movement between cells, allowing prostaglandins produced in one cell to act on neighboring cells. Transporters at barrier sites, including the blood-brain barrier, mediate directed movement of prostaglandins and their analogues between compartments. In erythrocytes, carrier-mediated transport contributes to the handling of prostaglandin E1 across the cell membrane, affecting its distribution in blood. Together, these uptake and efflux steps establish the spatial and temporal patterns of prostaglandin availability in tissues.
Regulation by interacting proteins
In simple terms: Other proteins can bind the transporter and change how actively it moves prostaglandins.
The transport activity of SLCO2A1 is modulated by interacting proteins such as annexin A2 and S100A10, which can influence transporter localization or function. This regulation links prostaglandin transport to membrane trafficking and signaling pathways that control transporter abundance at the cell surface. Such modulation provides a mechanism for cells to adjust prostaglandin uptake or efflux in response to physiological cues. Understanding these interactions is important for interpreting how transport capacity changes in disease or drug treatment.
Key Genes Involved in GO:0015732 prostaglandin transport
The genes and proteins below are experimentally implicated in prostaglandin transport (GO:0015732) or in its regulation, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLCO2A1 | Principal prostaglandin transporter mediating uptake and clearance of prostaglandins | Central target for structural, functional, and disease studies of prostaglandin transport |
| ANXA2 | Annexin A2 modulates SLCO2A1 transport activity | Candidate regulator of prostaglandin transport in cell models |
| S100A10 | S100A10 partners with annexin A2 to regulate SLCO2A1 | Potential modifier of transporter function and trafficking |
| PTGS1 | Prostaglandin synthesis enzyme upstream of transport | Context gene for interpreting transport phenotypes |
| PTGS2 | Inducible prostaglandin synthesis enzyme upstream of transport | Context gene for inflammation-related transport studies |
| PTGES | Terminal synthase for PGE2, a major transport substrate | Provides substrate for transport assays |
| HPGD | Prostaglandin dehydrogenase that metabolizes transported prostaglandins | Links transport to prostaglandin inactivation |
| ABCC4 | ATP-binding cassette transporter implicated in prostaglandin efflux | Candidate efflux transporter for functional studies |
| SLCO1A2 | Organic anion transporting polypeptide with prostaglandin transport capacity | Comparative transporter for specificity studies |
| SLCO1B1 | Organic anion transporting polypeptide family member | Reference for transporter family analysis |
| SLCO1B3 | Organic anion transporting polypeptide family member | Reference for transporter family analysis |
| SLCO2B1 | Organic anion transporting polypeptide family member | Reference for transporter family analysis |
| SLC22A8 | Organic anion transporter family member | Candidate for prostaglandin handling in kidney |
| SLC22A6 | Organic anion transporter family member | Candidate for prostaglandin handling in kidney |
| PTGFR | Prostaglandin F receptor downstream of transport | Readout for transport-dependent signaling |
| PTGER2 | PGE2 receptor downstream of transport | Readout for transport-dependent signaling |
| PTGER4 | PGE2 receptor downstream of transport | Readout for transport-dependent signaling |
How Is prostaglandin transport Regulated?
Prostaglandin transport is regulated at multiple levels. The activity of SLCO2A1 can be modulated by interacting proteins such as annexin A2 and S100A10, which influence transporter function and possibly its membrane localization. Transport is also influenced by substrate availability, since prostaglandin synthesis enzymes upstream of transport determine the amount of prostaglandin available for uptake or efflux. At barrier tissues, transport is regulated in a compartment-specific manner, as shown for prostaglandin E2 and D2 transport at brain barriers. In addition, the pharmacological properties of prostaglandin analogues depend on transporter expression and regulation, which affects their distribution and clearance. These layers of regulation allow cells to adjust prostaglandin transport capacity in response to physiological and pathological signals.
prostaglandin transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLCO2A1 | Prostaglandin clearance and inflammatory mediator control | Knockout and point-mutation cell lines with transport assays |
| ANXA2 | Regulation of prostaglandin transport activity | Knockdown or knockout cells with SLCO2A1 functional readouts |
| S100A10 | Modulation of SLCO2A1 transport function | Knockout cells and co-immunoprecipitation studies |
| HPGD | Prostaglandin metabolism downstream of transport | Overexpression and knockout models for transport-metabolism coupling |
| ABCC4 | Prostaglandin efflux and mediator release | Efflux assays in knockout and overexpression cells |
Prostaglandin transport and inflammation
Prostaglandin transport controls the local concentration of prostaglandins that drive inflammation, pain, and fever. By mediating uptake and clearance, transporters such as SLCO2A1 can terminate prostaglandin signaling and limit inflammatory responses. Conversely, altered transport capacity may prolong prostaglandin action and contribute to persistent inflammation. Experimental models that manipulate SLCO2A1 expression are therefore useful for testing causal roles in inflammatory phenotypes.
Prostaglandin transport at the blood-brain barrier
Transport of prostaglandins across the blood-brain barrier is pharmacologically significant because it determines central nervous system exposure to prostaglandins and their analogues. Carrier-mediated transport of prostaglandin E1 across the blood-brain barrier has been demonstrated in rats, indicating that specific transport mechanisms regulate brain prostaglandin levels. Prostaglandin E2 and D2 transport at brain barriers further shapes neuroinflammatory and fever responses. These findings support studying prostaglandin transporters as modulators of central nervous system drug delivery and neuroinflammation.
Prostaglandin transport in blood cells
Erythrocytes participate in prostaglandin handling through carrier-mediated transport across their membranes. Transport of prostaglandin E1 across the rat erythrocyte membrane has been characterized, showing that blood cells contribute to prostaglandin distribution and clearance. This process can influence the circulating pool of prostaglandins and the pharmacokinetics of prostaglandin analogues. Erythrocyte transport assays are therefore a useful model for studying prostaglandin transport mechanisms.
Prostaglandin transport and drug disposition
Because SLCO2A1 transports both prostaglandins and certain drugs, prostaglandin transport is relevant to drug disposition and drug-drug interactions. Structural studies of SLCO2A1 have revealed how prostaglandins and drugs share a transport pathway, which helps explain substrate overlap. Pharmacological modulation of prostaglandin transport at barriers can alter the distribution of prostaglandin analogues. This makes prostaglandin transporters important considerations in the development of prostaglandin-related therapeutics.
From prostaglandin transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLCO2A1 mediate prostaglandin uptake in a specific cell type? | SLCO2A1 knockout cell line with radiolabeled or fluorescent prostaglandin uptake assays |
| Which residues are required for SLCO2A1 transport activity? | Point-mutation knock-in of SLCO2A1 at candidate residues with transport assays |
| How does SLCO2A1 localization affect transport? | Tagged knock-in of SLCO2A1 for imaging and membrane fractionation |
| Does annexin A2 regulate prostaglandin transport? | ANXA2 knockout or overexpression cells with SLCO2A1 activity readouts |
| Can prostaglandin transport be measured at barriers? | In vitro blood-brain barrier models and erythrocyte transport assays |
| Does prostaglandin transport alter downstream signaling? | Overexpression of SLCO2A1 with receptor activation and second messenger readouts |
How to Study the prostaglandin transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled prostaglandin uptake assay | Carrier-mediated transport into cells | Characterizing SLCO2A1 activity and mutants |
| Fluorescent prostaglandin transport assay | Real-time uptake or efflux | Live-cell imaging of transport dynamics |
| Cryo-EM and crystallography | Transporter structure and substrate binding | Mechanistic studies of SLCO2A1 |
| Site-directed mutagenesis | Functional role of specific residues | Testing transport mechanism hypotheses |
| Co-immunoprecipitation | Protein-protein interactions | Identifying regulators of SLCO2A1 |
| RNA sequencing | Transporter gene expression profiles | Tissue and condition-specific expression analysis |
| CRISPR knockout screening | Genes required for transport phenotypes | Discovery of novel transport regulators |
| Blood-brain barrier transport assay | Barrier permeability to prostaglandins | Central nervous system drug delivery studies |
Transport assays with labeled prostaglandins
Direct measurement of prostaglandin transport typically uses radiolabeled or fluorescent prostaglandin substrates in cell monolayers or membrane vesicles. These assays quantify uptake or efflux and can be combined with transporter inhibitors to establish carrier-mediated mechanisms. They are widely used to characterize SLCO2A1 activity and to compare mutant transporters generated by CRISPR. Transport assays at barriers, such as blood-brain barrier models, extend these measurements to compartment-specific questions.
Structural and biochemical analysis of transporters
Structural studies of human SLCO2A1 have provided atomic-level insights into substrate binding and the transport cycle. Biochemical approaches, including mutagenesis and binding assays, complement structures by testing the functional consequences of specific residues. These methods help explain how prostaglandins and drugs are recognized and translocated. They also guide the interpretation of disease-associated variants in transport genes.
Protein interaction and regulation studies
Co-immunoprecipitation, pull-down, and proximity labeling can identify proteins that interact with prostaglandin transporters. Such approaches revealed that annexin A2 and S100A10 modulate SLCO2A1 transport activity. Functional follow-up using knockout or knockdown cells tests whether these interactions change transport rates. These methods link prostaglandin transport to broader cellular regulation.
Expression profiling and functional genomics
RNA sequencing and quantitative PCR can profile transporter expression across tissues and conditions to identify where prostaglandin transport is active. CRISPR library screening can systematically test which genes modify prostaglandin transport or its downstream effects. Combining expression data with functional transport assays helps prioritize candidate regulators. These approaches are particularly useful for discovering new components of prostaglandin transport pathways.
How CRISPR Can Be Used to Study GO:0015732 prostaglandin transport
Knockout
CRISPR knockout of SLCO2A1 or candidate regulators provides a clean loss-of-function background to test whether a gene is required for prostaglandin transport. Knockout cells can be challenged with labeled prostaglandins to measure residual transport and to identify compensatory transporters. This approach is also useful for validating interactions, such as the contribution of annexin A2 or S100A10 to SLCO2A1 activity. Knockout models therefore establish causal necessity for genes in the prostaglandin transport process.
Point Mutation
Point-mutation knock-in allows precise testing of residues implicated in substrate binding or conformational changes of SLCO2A1. By introducing disease-associated or mechanism-based mutations, researchers can measure effects on transport kinetics and substrate specificity. Such models are valuable for linking structural predictions to functional outcomes. They also help distinguish transport defects from changes in protein expression or localization.
Knock-in
Tagged knock-in of SLCO2A1 or interacting proteins enables visualization and biochemical isolation of the transporter in its native context. Fluorescent or affinity tags support imaging of transporter trafficking and interaction studies without overexpression artifacts. Knock-in of reporter alleles can also provide readouts of transporter promoter activity. These models are useful for studying regulation of prostaglandin transport at endogenous expression levels.
Overexpression
Overexpression of SLCO2A1 or candidate transporters increases transport capacity and can reveal gain-of-function phenotypes. This approach is useful for producing sufficient protein for biochemical and structural studies. Overexpression in barrier models can test whether increased transport alters prostaglandin distribution across cell layers. Combined with knockout data, overexpression helps establish sufficiency in prostaglandin transport.
How EDITGENE Supports prostaglandin transport Research
Researchers studying prostaglandin transport-related genes often need to determine whether a candidate gene is causally involved in uptake, efflux, or regulation of prostaglandin movement. EDITGENE provides CRISPR-based cell models and screening services that allow precise manipulation of SLCO2A1 and related genes, enabling functional tests of transport mechanisms and disease hypotheses.
Contact EDITGENE today to design your custom CRISPR model for prostaglandin transport research.
Frequently Asked Questions About prostaglandin transport
What is prostaglandin transport GO:0015732?
GO:0015732 prostaglandin transport is the directed movement of prostaglandins into, out of, or within a cell, or between cells, by means of a transporter or pore.
What genes are involved in prostaglandin transport?
SLCO2A1 is the principal prostaglandin transporter, and ANXA2 and S100A10 regulate its activity; other transporters such as ABCC4 and SLCO family members have also been implicated.
Which protein is the main prostaglandin transporter?
SLCO2A1, also known as the prostaglandin transporter or PGT, is the best-characterized carrier for prostaglandin uptake and clearance.
How is prostaglandin transport measured experimentally?
Transport is commonly measured with radiolabeled or fluorescent prostaglandin uptake and efflux assays in cells or membrane vesicles.
Why is prostaglandin transport important in the brain?
Carrier-mediated transport at the blood-brain barrier controls central nervous system exposure to prostaglandins and their analogues.
Does prostaglandin transport occur in red blood cells?
Yes, prostaglandin E1 transport across the rat erythrocyte membrane is carrier-mediated, showing that erythrocytes participate in prostaglandin handling.
How is SLCO2A1 transport activity regulated?
SLCO2A1 activity can be modulated by interacting proteins such as annexin A2 and S100A10.
What diseases are linked to prostaglandin transport?
Altered prostaglandin transport has been linked to inflammation, barrier function, and drug disposition, with relevance to neuroinflammation and prostaglandin-related therapeutics.
Can CRISPR be used to study prostaglandin transport?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of SLCO2A1 and related genes in transport assays.
What is the difference between prostaglandin synthesis and prostaglandin transport?
Prostaglandin synthesis produces prostaglandins enzymatically, whereas prostaglandin transport moves the synthesized prostaglandins across membranes to control their availability.
Conclusion
Prostaglandin transport (GO:0015732) is a genetically and pharmacologically important process that controls the distribution and clearance of lipid mediators such as PGE2 and PGD2. The transporter SLCO2A1 is central to this process, and its structure, regulation, and disease relevance are increasingly well defined. Studying prostaglandin transport with CRISPR-based cell models and transport assays provides a direct route to understanding inflammation, barrier biology, and drug disposition. Continued work on transport mechanisms and regulators will help translate this knowledge into therapeutic strategies.
References
- 1. Schuster VL. 2002. Prostaglandin transport.. Prostaglandins Other Lipid Mediat 68-69:633-47 PMID: 12432949
- 2. Xia Z et al.. 2025. Structure and transport mechanism of the human prostaglandin transporter SLCO2A1.. Nat Commun 16(1):8124 PMID: 40885756
- 3. Schuster VL. 1998. Molecular mechanisms of prostaglandin transport.. Annu Rev Physiol 60:221-42 PMID: 9558462
- 4. Joshi C et al.. 2026. Structural basis for prostaglandin and drug transport via SLCO2A1.. Nat Commun 17(1) PMID: 41862483
- 5. Tachikawa M et al.. 2014. Pharmacological significance of prostaglandin E2 and D2 transport at the brain barriers.. Adv Pharmacol 71:337-60 PMID: 25307222
- 6. Nakamura Y et al.. 2024. Modulation of prostaglandin transport activity of SLCO2A1 by annexin A2 and S100A10.. Am J Physiol Cell Physiol 326(4):C1042-C1053 PMID: 38372137
- 7. Taogoshi T et al.. 2005. Transport of prostaglandin E1 across the blood-brain barrier in rats.. J Pharm Pharmacol 57(1):61-6 PMID: 15638994
- 8. Taogoshi T et al.. 2008. Transport of prostaglandin E1 across rat erythrocyte membrane.. Biol Pharm Bull 31(6):1288-91 PMID: 18520071
